The Medicare GLP-1 Bridge Is Live: $50 a Month, Three Products, One Formulation Catch

What the Bridge Actually Is, and Why It Is a First

The Medicare GLP-1 Bridge is a time-limited CMS demonstration, not a permanent benefit. It runs from July 1, 2026 through December 31, 2027, and it operates alongside rather than inside Part D coverage. That structural detail drives most of the program's quirks.

Under the Bridge, the prescriber submits a coverage determination request and prescription to a single CMS central processor rather than to the beneficiary's Part D plan. That central processor handles prior authorization, claims adjudication, and payment to pharmacies. Pharmacies collect the $50 copayment at the counter and submit claims to the same central processor using a designated BIN and PCN. Because the demonstration operates outside the Part D benefit, Part D plans are not responsible for Bridge drugs, and the beneficiary's plan is not the gatekeeper for access.

The money moves in two directions. CMS reimburses the pharmacy at no lower than the wholesale acquisition cost of the drug, less the beneficiary's $50 copay, plus a dispensing fee and sales tax. Manufacturer participation is voluntary, and participating manufacturers agreed to a negotiated net price of $245 per 30-day supply, owing money back to CMS for the difference between what they charged and that $245 figure. The roughly $195 balance between the $245 net price and the beneficiary's $50 copay is carried by CMS, not billed to the patient. It is worth being precise about this, because "the manufacturers pay the difference" is a common shorthand and it is not what the arrangement does.

This is the first time Medicare has paid for GLP-1s used for weight management. That framing matters, because it also explains who is left out, which is covered further down.

The Three Covered Products, and the Zepbound Formulation Catch

The covered list is short and formulation-specific. This is where most avoidable coverage problems originate.

|---|---|---|---|

The Zepbound restriction is the one to circle. The KwikPen is a multi-dose, single-patient-use prefilled pen that holds four fixed weekly doses, so one pen covers a 28-day supply. Zepbound is also sold as a single-dose injector pen and as a single-dose vial used with a syringe, and neither of those is on the Bridge list.

The consequence is structural rather than a matter of paperwork. The Bridge will not pay for a non-covered form, and Part D is separately barred by statute from covering a GLP-1 prescribed for weight loss, so there is no second door to try. The practical fallback for someone on a non-covered form is the cash price, which is the difference between a $50 copay and several hundred dollars a month. Whether a prescription can or should be written for a different form is a clinical decision for the prescribing provider.

Foundayo is the newest name on the list. The FDA approved it in April 2026 as a once-daily oral GLP-1 receptor agonist for adults with obesity, or overweight with weight-related conditions, making it the second oral GLP-1 available for weight management after the Wegovy tablet was approved in December 2025. If you are unfamiliar with orforglipron and how it compares to oral semaglutide, we covered the trial data and dosing rules separately in [orforglipron vs oral semaglutide](/blog/orforglipron-vs-oral-semaglutide-foundayo).

Who Qualifies: Three BMI Tiers Plus Attestation

Eligibility is not open to everyone on Medicare with excess weight. The beneficiary must be enrolled in Part D, be at least 18 years of age, and fall into one of three clinical categories CMS defined.

|---|---|---|

Part D enrollment includes standalone prescription drug plans and Medicare Advantage plans with drug coverage, and CMS has indicated certain special needs plans and dually eligible beneficiaries are in scope.

The prescriber must attest that the beneficiary meets one of those categories and that the drug is being prescribed to reduce excess body weight and to maintain that weight reduction. One nuance is worth knowing: the attestation is made against the clinical picture at the time GLP-1 therapy was first initiated, even when that initial prescription predates July 1, 2026. Someone who started therapy in 2024 at a BMI of 37 and has since come down to 31 is not automatically disqualified by their current number, because the prescriber attests to the BMI at initiation. How that applies to any individual is a clinical judgment for the prescribing provider, not something to assume from a chart.

Who Is Excluded Even With a Qualifying BMI

This is the part that surprises people. Beneficiaries diagnosed with type 2 diabetes, obstructive sleep apnea, or noncirrhotic MASH are not eligible for the Bridge, even when they meet the BMI and comorbidity criteria above.

The logic is administrative rather than clinical. Those indications are already eligible for standard Part D coverage, so CMS routes those patients back to their plan. The same applies to a GLP-1 prescribed for cardiovascular risk reduction, which is a Part D-covered use rather than a Bridge use. The Bridge exists only to fill the weight-management gap the statute leaves open. Zepbound's approval for moderate-to-severe obstructive sleep apnea, which we covered in [Zepbound for sleep apnea](/blog/tirzepatide-zepbound-sleep-apnea-osa-2026), is exactly the kind of indication that moves a person out of the Bridge and back into Part D. An existing Part D prescription for a GLP-1 also removes Bridge eligibility.

KFF analyzed 2023 Medicare claims to estimate the reach. Roughly 9.7 million Part D enrollees met the clinical criteria, but about 5.9 million were ineligible because of a type 2 diabetes, obstructive sleep apnea, or MASH diagnosis, or because they had filled a Part D-covered GLP-1 prescription. That left an estimated 3.8 million eligible beneficiaries, about 39 percent of those meeting the clinical criteria and about 8 percent of the 47.5 million Part D enrollees. KFF noted the figure is somewhat conservative for Medicare Advantage enrollees, because diagnoses appearing only on Medicare Advantage chart reviews were not used to build the condition flags.

What the $50 Does Not Do

The copay is flat at $50 per 30-day supply regardless of dose and regardless of which phase of the Part D benefit the beneficiary is in. That is genuinely simple. What it does not do is accumulate.

For context on cash-pay alternatives outside the Bridge, direct-to-consumer channels post their own prices. As of early August 2026, reported figures include roughly $199 for the first two monthly fills of Wegovy injection and about $349 to $399 per month thereafter depending on dose, about $149 per month for the Wegovy tablet at lower strengths with the 4 mg strength scheduled to rise to about $199 after August 31, 2026, and roughly $299 to $499 per month for Zepbound depending on dose. Some reporting has cited figures above that range for certain Zepbound presentations. These numbers move, differ between TrumpRx, LillyDirect, and retail, and vary by dose and formulation, so treat any single figure as a snapshot rather than a fixed rate. Cash spending outside the Bridge does not count toward Part D out-of-pocket totals either.

The April 21 Change: Extended to 2027, Part D BALANCE Delayed

The Bridge was originally scheduled to run only from July 1 through December 31, 2026, as a transition into the broader BALANCE model. On April 21, 2026, CMS confirmed two things at once. First, the Bridge would run through December 31, 2027 instead. Second, Medicare Part D implementation of the BALANCE model was indefinitely delayed.

The reason was participation. CMS could only proceed with the Medicare arm in 2027 if Part D plan sponsors representing 80 percent of Part D enrollment applied, and sponsors had until April 20, 2026 to do so. That threshold was not met, so the Part D arm did not move forward.

Had it launched, cost-sharing would have looked different: $245 per 30-day supply in the deductible phase, then $50 per month in enhanced or employer plans or $125 per month in basic plans, and $0 once the beneficiary reached the out-of-pocket maximum. Extending the flat $50 Bridge instead keeps the simpler structure in place while CMS gathers data.

The Medicaid arm did proceed. It began May 1, 2026 with rolling state implementation running through January 1, 2027, states had until July 31, 2026 to apply, and the model is authorized through December 31, 2031. Medicaid's covered list is wider than Medicare's: all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, plus the KwikPen formulation of Zepbound. Negotiated Medicaid net prices remain confidential to participating states. So the Zepbound formulation restriction carries across both programs, but the Medicaid list adds three products Medicare's Bridge does not include.

What to Track

Coverage status is not a biomarker, but it changes the shape of a tracking record, because a coverage gap can interrupt a protocol and show up in the data weeks later. Two categories are worth logging.

On the coverage side, keep a dated record of the exact product and formulation on the current prescription, including whether a Zepbound prescription is written for the KwikPen or a single-dose form, the prior authorization submission and approval dates, and any change in diagnosis that could move someone in or out of Bridge eligibility. That record is what makes a prescriber conversation efficient instead of exploratory.

On the lab side, the markers commonly followed during GLP-1 therapy are the same ones discussed in our [GLP-1 lab monitoring panel](/blog/glp1-lab-monitoring-panel), and none of this is a recommendation to test:

Weight and BMI belong in the same record, since BMI at therapy initiation is what the attestation rests on. Keeping the history in one place, rather than reconstructing it from memory during an appointment, is the practical difference between a five-minute conversation and a delayed prior authorization. [Track your labs, weight history, and protocol timeline in one place with MyProtocolStack.](/auth/login?mode=signup)

For Coaches and Practitioners With Clients Over 65

If you work with clients who are on Medicare or approaching it, the Bridge creates one concrete, non-clinical task: find out which product form each client is actually on.

A client on Zepbound single-dose vials or single-dose pens is on a formulation the Bridge does not cover. A client turning 65 mid-protocol may be moving from commercial coverage, where single-dose pens are common, into a program that only pays for the KwikPen. Neither situation is yours to solve, and recommending a formulation change is outside a coaching scope. What you can do is surface it early so the client raises it with their prescriber before a coverage gap hits, rather than after a rejected claim at the pharmacy.

The same applies to diagnosis changes. A client who receives a new obstructive sleep apnea or type 2 diabetes diagnosis moves out of Bridge eligibility and back toward Part D. That is a routing change with real cost consequences, and it is the kind of thing a well-kept tracking record catches. Note it, hand it to the client, and let the clinician decide.

Frequently Asked Questions

Which GLP-1 drugs are covered by the Medicare GLP-1 Bridge?

Three products are covered. All formulations of Foundayo (orforglipron), all formulations of Wegovy including both the injection and the tablet, and the KwikPen formulation of Zepbound only. Zepbound single-dose vials and single-dose pen forms are not covered under the Bridge. The Medicaid arm of the BALANCE model uses a wider list that also includes Mounjaro, Ozempic, and Rybelsus, but it carries the same Zepbound KwikPen restriction.

How much does the Medicare GLP-1 Bridge cost per month?

Eligible beneficiaries pay a flat $50 copay per 30-day supply regardless of dose and regardless of Part D benefit phase, set against a negotiated net price of $245 per month. CMS carries the roughly $195 balance and participating manufacturers rebate CMS down to the $245 net price. Important limits apply: the $50 does not count toward the Part D deductible or toward true out-of-pocket costs, so it does not move a beneficiary toward the annual cap of $2,100 in 2026, and beneficiaries receiving the Low-Income Subsidy, also called Extra Help, receive no reduction on the $50.

Who is eligible for the Medicare GLP-1 Bridge?

A beneficiary must be enrolled in Medicare Part D, be at least 18 years old, and fall into one of three clinical categories: BMI of 35 or higher with no additional condition required, BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above, or BMI of 27 or higher with prediabetes, prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease. The prescriber must attest that the beneficiary meets one of these categories, assessed at the time GLP-1 therapy was first initiated.

Why would someone with a qualifying BMI still be excluded?

Beneficiaries with a diagnosis of type 2 diabetes, obstructive sleep apnea, or noncirrhotic MASH are not eligible for the Bridge, and neither are those with an existing Part D prescription for a GLP-1. Those indications already qualify for standard Part D coverage, so CMS routes those patients back to their plan. KFF estimated from 2023 claims that roughly 9.7 million Part D enrollees met the clinical criteria but about 5.9 million were excluded on these grounds, leaving about 3.8 million eligible, or roughly 8 percent of Part D enrollees.

How long does the Medicare GLP-1 Bridge run, and what happened to BALANCE?

The Bridge launched July 1, 2026. On April 21, 2026, CMS confirmed it would run through December 31, 2027 rather than ending December 31, 2026, and that Medicare Part D implementation of the broader BALANCE model was indefinitely delayed after Part D sponsors representing 80 percent of Part D enrollment failed to apply by the April 20, 2026 deadline. The Medicaid arm of BALANCE did proceed, beginning May 1, 2026 with rolling state implementation through January 1, 2027.

Sources

1. KFF, "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge." https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/

2. CMS, "Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries

3. CMS, "Medicare GLP-1 Bridge: Information for Part D Plans." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans

4. CMS, "Medicare GLP-1 Bridge: Information for Providers." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers

5. KFF, "Nearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridge." https://www.kff.org/medicare/nearly-four-million-medicare-beneficiaries-met-the-eligibility-criteria-in-2023-for-the-medicare-glp-1-bridge/

6. KFF Health News, "Cheaper GLP-1s Arrive for Some on Medicare." https://kffhealthnews.org/medicare/cheaper-glp-1-weight-loss-medicare-bridge-wegovy-zepbound-foundayo/

7. Forbes, "Medicare's GLP-1 Bridge Program Offers Access, But Isn't Straightforward." https://www.forbes.com/sites/joshuacohen/2026/08/01/medicares-glp-1-bridge-program-offers-access-but-isnt-straightforward/

8. Becker's, "CMS pauses weight-loss BALANCE model indefinitely for Medicare." https://www.beckershospitalreview.com/glp-1s/cms-pauses-weight-loss-balance-model-indefinitely-for-medicare/

9. AMCP, "Regulatory NewsBREAK: CMS Releases Frequently Asked Questions on the Medicare GLP-1 Bridge." https://www.amcp.org/regulatory-newsbreak-cms-releases-frequently-asked-questions-medicare-glp-1-bridge

10. Eli Lilly, "FDA approves Lilly's Foundayo (orforglipron)." https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

11. Medicare Rights Center, "GLP-1 Weight-Loss Drug Demonstration Begins July 2026." https://www.medicarerights.org/medicare-watch/2026/06/04/glp-1-weight-loss-drug-demonstration-begins-july-2026

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*